Oren Gilad - Jul 28, 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: President, CEO
Signature: /s/ Scott M. Coiante, attorney-in-fact
Stock symbol: APRE
Transactions as of: Jul 28, 2022
Transactions value $: $0
Form type: 4
Date filed: 8/1/2022, 05:01 PM
Previous filing: May 26, 2022
Next filing: Mar 13, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APRE	Common Stock	Award	$0	+101K	+44.23%	$0.00	330K	Jul 28, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APRE	Stock Option (right to Buy)	Award	$0	+149K		$0.00	149K	Jul 28, 2022	Common Stock	149K	$1.09	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 33,766 shares on July 28, 2023, (ii) 33,767 shares on July 28, 2024 and (iii) 33,767 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2	Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

Content

These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 33,766 shares on July 28, 2023, (ii) 33,767 shares on July 28, 2024 and (iii) 33,767 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.